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Introduction: This exploratory subgroup analysis of the
MARQUEE study evaluated the efficacy and safety of erlo-
tinib plus tivantinib in patients with EGFR-mutant NSCLC.
Methods: Patients with advanced, nonsquamous, EGFR and
mesenchymal-epithelial transition inhibitor–naive NSCLC
previously treated with one or two lines of systemic therapy
were randomized to oral erlotinib (150 mg once daily) plus
tivantinib (360 mg twice daily) or to erlotinib plus placebo.
The primary end point was overall survival.
Results: Among 1048 patients enrolled, 109 (10.4%) had
EGFR-mutant disease. Erlotinib plus tivantinib improved
progression-free survival in this subpopulation; median
progression-free survival was 13.0 months for erlotinib plus
tivantinib (n¼ 56) and 7.5 months for erlotinib plus placebo
(n ¼ 53) (hazard ratio ¼ 0.49, 95% confidence interval:
0.31–0.77). Deaths occurred in 73 patients (67%), and me-
dian overall survival was 25.5 months in the erlotinib plus
tivantinib arm versus 20.3 months in the erlotinib plus pla-
cebo arm (hazard ratio ¼ 0.68, 95% confidence interval:
0.43–1.08). Common adverse events included diarrhea, rash,
and asthenia. Neutropenia and febrile neutropenia were
more common with erlotinib plus tivantinib.
Conclusions: Erlotinib plus tivantinib was tolerable and
showed improved efficacy over erlotinib monotherapy in
previously treated EGFR-mutant NSCLC.
 2018 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.Keywords: Lung cancer; nonsquamous; MET inhibitor;
tivantinib; erlotinib; EGFRIntroduction
EGFR-targeted tyrosine kinase inhibitors (TKIs)
are indicated as first-line therapy for NSCLC with acti-
vating EGFR mutations, including exon 19 deletions
or exon 21 (L858R) substitutions.1 The OPTIMAL,
EURTAC, and ENSURE trials showed that erlotinib is
highly effective in patients with previously untreated,Journal of Thoracic Oncology Vol. 13 No. 6: 849-854
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to EGFR TKIs and relapse develop in most patients.5
Mesenchymal-epithelial transition (MET) receptor
overexpression is common in nonsquamous NSCLC5,6
and is associated with a poor prognosis.7,8 Importantly,
MNNG HOS Transforming gene (MET) amplification is
associated with resistance to EGFR TKIs.7,9 In vitro, in-
hibition of MET in tumor cells with acquired resistance
to EGFR inhibitors restored sensitivity to EGFR in-
hibitors and reduced cell growth.9 On the basis of pre-
clinical models, disruption of MET signaling with small
interfering RNA, TKIs, or antibodies inhibits the growth
of NSCLC tumor cells and xenografts and can potentially
overcome resistance.10
Tivantinib is a selective, oral, small-molecule MET
inhibitor with an adenosine triphosphate–independent
binding mechanism.11,12 In the MARQUEE trial, in which
approximately 90% of patients were EGFR wild type,
erlotinib plus tivantinib significantly improved
progression-free survival (PFS) (median PFS 3.6 versus 1.9
months; hazard ratio [HR] ¼ 0.74, p < 0.001) but did not
significantly improve overall survival (OS) versus that with
erlotinib plus placebo.6 A preplanned exploratory analysis
of the subgroup of 211 patients with high tumor MET
expression showed a potential OS benefit favoring erlotinib
plus tivantinib (median OS 9.3 versus 5.9 months;
HR ¼ 0.70, 95% confidence interval [CI]: 0.49–1.01).6
Given that erlotinib monotherapy has activity in pa-
tients with an activating EGFR mutation, tivantinib plus
erlotinib might have greater additive activity and may
help to overcome or block acquired resistance to erlo-
tinib. The objective of this exploratory analysis of
MARQUEE was to evaluate the efficacy and safety of
erlotinib plus tivantinib in the subgroup of 109 patients
with EGFR-mutant NSCLC.
Patients and Methods
Patients
Patient characteristics have been described previ-
ously, as have biomarker analyses.6 Patients were at
least 18 years old with histologically or cytologically
confirmed inoperable locally advanced or metastatic
nonsquamous NSCLC.6 They had received one or two
prior chemotherapy regimens with a platinum-based
doublet and no EGFR TKI or MET inhibitor therapy. All
patients were tested by polymerase chain reaction assay
for exon 19 deletion, T790M, L858R, L861Q, G719X,
S768I, and exon 20 insertion EGFR mutations before
randomization, and all had an EGFR mutation.
Study Design, Treatment, and Objectives
Patients were stratified on the basis of number of
prior therapies, sex, smoking status, and EGFR and KRASmutation status and were randomized 1:1 to oral erlo-
tinib (150 mg once daily) plus tivantinib (360 mg twice
daily) or erlotinib plus placebo. Exploratory end points
included PFS, OS, association between EGFR mutation
and PFS or OS, objective response rate, and safety.
MARQUEE met the criteria for futility at the preplanned
interim analysis, and the main study was discontinued.
Results in the EGFR-mutant subgroup were not mature,
and it was agreed to continue treatment and follow-up in
that subgroup.6
Statistical Analysis
A data cut for this subgroup was prespecified to
occur after approximately 70% of patients had died,
which was projected to occur approximately 2.5 years
after the last patient was randomized.
Results
Patient Population and Disposition
Among 1048 patients enrolled, 109 (10.4%) had an
EGFRmutation and were included in the current analysis:
56 were randomized to erlotinib plus tivantinib and
53 to erlotinib plus placebo. The most common EGFR
mutation was an exon 19 deletion (n ¼ 55), followed by
L858R (n ¼ 39); five patients had an exon 20 insertion,
and 10 patients had other EGFR mutations or the specific
mutation was not reported (Table 1). Patient character-
istics were generally similar between treatment groups.
At the time of the analysis, six patients (10.7%) in
the erlotinib plus tivantinib group were still receiving
study treatment 31 to 40 months from randomization,
compared with none in the erlotinib plus placebo
group. The EGFR mutations in the six patients with
ongoing treatment included four with exon 19 deletions,
one with L858R, and one exon 20 insertion. The most
common reasons for discontinuation were disease
progression and adverse events (AEs) (Table 2). More
patients discontinued treatment because of disease
progression in the erlotinib plus placebo group, whereas
more discontinued because of AEs in the erlotinib plus
tivantinib group.
Efficacy
Median PFS was longer in the erlotinib plus tivantinib
group than in the erlotinib plus placebo group (13.0
versus 7.5 months, respectively; HR ¼ 0.49, 95% CI:
0.31–0.77) (Fig. 1A). OS was similar in the erlotinib
plus tivantinib group and in the erlotinib plus placebo
group (median 25.5 versus 20.3 months, respectively;
HR ¼ 0.68, 95% CI: 0.43–1.08) (Fig. 1B). The objective
response rate was 61% (95% CI: 48%–72%) in the
erlotinib plus tivantinib group versus 43% (95% CI:
31%–57%) in the erlotinib plus placebo group (Table 3).
Table 2. Patient Disposition
Reason for
Treatment
Discontinuation
Tivantinib
þ Erlotinib
(n ¼ 56)
Placebo
þ Erlotinib
(n ¼ 53)
Ongoing, n (%) 6 (10.7) 0
Reason for discontinuation, n (%) 50 (89.3) 53 (100.0)
Progressive disease 25 (44.6) 39 (73.6)
Clinical progression 4 (7.1) 4 (7.5)
Adverse event 10 (17.9) 2 (3.8)
Death 0 2 (3.8)
Lost to follow-up 0 0
Protocol violation 0 0
Withdrawal of consent 2 (3.6) 1 (1.9)
Other 1 (1.8) 2 (3.8)
Missing 8 (14.3) 3 (5.7)
Table 1. Demographics of Patients with EGFR Mutations in
the MARQUEE Trial
Characteristic
Tivantinib þ
Erlotinib
(n ¼ 56)
Placebo þ
Erlotinib
(n ¼ 53)
Median age,
y (range)
59.5 (34–84) 65.0 (38–82)
Sex, n (%)
Male 24 (42.9) 25 (47.2)
Female 32 (57.1) 28 (52.8)
ECOG performance status, n (%)
0 21 (37.5) 17 (32.1)
1 35 (62.5) 36 (67.9)
Smoking history, n (%)
Current 3 (5.4) 3 (5.7)
Former 26 (46.4) 18 (34.0)
Never 27 (48.2) 32 (60.4)
Race, n (%)
White 46 (82.1) 44 (83.0)
Asian 2 (3.6) 2 (3.8)
Other/unknown 8 (14.3) 7 (13.2)
No. of prior regimens, n (%)
1 39 (69.6) 40 (75.5)
2 17 (30.4) 13 (24.5)
Type of EGFR
mutation, n (%)
Exon 19 deletion 32 (57.1) 23 (43.4)
L858R 18 (32.1) 21 (39.6)
Exon 20 insertion 3 (5.4) 2 (3.8)
Othera 3 (5.4) 7 (13.2)
MET expression, n (%)b
High 8 (14.3) 12 (22.6)
Low 16 (28.6) 10 (18.9)
Unknown 32 (57.1) 31 (58.5)
MET amplification, n (%)c
High 2 (3.6) 3 (5.7)
Low 27 (48.2) 29 (54.7)
Unknown 27 (48.2) 21 (39.6)
KRAS, n (%)
Positive 0 2 (3.8)
Negative 54 (96.4) 49 (92.5)
Unknown 2 (3.6) 2 (3.8)
aOther includes three patients with a G719X mutation, two patients with a
S768I mutation, one patient with a G719X and S768I mutation; for four pa-
tients, a specific mutation was not reported.
bMET expression was defined as positive or high if membranous immunohis-
tochemical staining intensity was 2 or higher in at least 50% of tumor cells.
cMET amplification by fluorescence in situ hybridization was defined as
positive or high if the MET gene copy number was 4 or higher.
ECOG, Eastern Cooperative Oncology Group; MET, mesenchymal-epithelial
transition; MET, MNNG HOS Transforming gene.
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erlotinib plus tivantinib prolonged PFS (HR ¼ 0.42, 95%
CI: 0.23–0.77) with a numerical improvement in OS
(HR ¼ 0.68, 95% CI: 0.35–1.32). The improvements in
PFS (HR ¼ 0.80, 95% CI: 0.37–1.74) and OS (HR ¼ 0.86,
95% CI: 0.39–1.92) were less pronounced in the 39
patients with the L858R EGFRmutation. The subgroup of15 patients with exon 20 insertions or other EGFR mu-
tations was too small and heterogeneous to allow for a
meaningful analysis of PFS and OS outcomes.
Safety
The most common treatment-emergent AEs of any
grade were diarrhea, rash, and asthenia, which occurred
at similar rates in both treatment groups (Table 4). Both
neutropenia and febrile neutropenia were more common
in patients receiving erlotinib and tivantinib. The most
common (>5%) treatment emergent AEs of grade 3 or
higher were neutropenia (14.3%), asthenia or fatigue
(5.4%), and anemia (5.4%) in patients receiving erlotinib
plus tivantinib and anemia, neutropenia, asthenia or fa-
tigue, dermatitis acneiform, and rash (5.7% each) in
patients receiving erlotinib plus placebo. One death from
pneumonia in a patient receiving erlotinib plus placebo
was reported as treatment related. The safety profile of
erlotinib plus tivantinib in this subgroup was similar to
that observed in the overall study population despite the
longer duration of therapy, which included patients
treated with tivantinib for more than 3 years.6
Discussion
Studies have sought to determine whether MET in-
hibition can overcome or block emergence of resistance
to EGFR inhibitors and prolong time to progression in
NSCLC. This hypothesis is based on evidence that MET
amplification is associated with resistance to EGFR in-
hibitors and inhibition of MET signaling can restore
sensitivity to EGFR inhibitors.7,9 Several clinical trials
have suggested a potential clinical benefit of combining a
MET inhibitor with an EGFR inhibitor in NSCLC.6,13,14
These studies suggest that the benefit of this combina-
tion is greatest in patients with high MET expression or
amplification, but the data are inconsistent. The current
exploratory analysis was an attempt to clarify the benefit
Figure 1. Progression-free survival (PFS) (A) and overall survival (B) in patients with EGFR-mutant disease enrolled in the
MARQUEE study. CI, confidence interval; HR, hazard ratio.
Table 3. Response Rate and Duration of Response
Response
Tivantinib þ
Erlotinib (n ¼ 56)
Placebo þ
Erlotinib (n ¼ 53)
Overall response
rate (CR þ PR)
60.7% 43.4%
Patients with
subsequent PD
39.3% 39.6%
Median duration of
response, weeks
(min, max)
51.14 (3.4, 148.1) 39.43 (8.3, 112.0)
CR, complete response; PD, progressive disease; PR, partial response.
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inhibitor in subsets of patients defined by EGFRmutation
status regardless of MET expression.
The results suggest that tivantinib may augment the
activity of erlotinib against tumors with an activating
EGFR mutation, perhaps by overcoming intrinsic
resistance to erlotinib mediated by MET expression or
by preventing the emergence of MET expression.
Treatment groups were fairly well balanced for MET
expression, although more patients in the erlotinib plus
placebo group had high MET expression (22.6%) than
in the erlotinib plus tivantinib group (14.3%). In
patients with EGFR mutations, erlotinib plus tivantinib
was tolerable and improved PFS versus that in patients
receiving erlotinib plus placebo, as in the overall study
population, without improving OS. The benefit inpatients receiving erlotinib plus tivantinib was most
evident in patients with an exon 19 deletion; such
patients were previously shown to have a greater
Table 4. Percentage of Patients with Treatment-Emergent Adverse Events with a Frequency of 20% or More or of Special
Interest
MedDRA System, Organ,
Class/Preferred Term
All Grades, % Grades 3, %
Tivantinib þ Erlotinib
(n ¼ 56)
Placebo þ Erlotinib
(n ¼ 53)
Tivantinib þ Erlotinib
(n ¼ 56)
Placebo þ Erlotinib
(n ¼ 53)
Blood and Lymphatic
Anemia 21.4 9.4 5.4 5.7
Febrile neutropenia 3.6 0 3.6 0
Neutropenia 26.8 9.4 14.3 5.7
Thrombocytopenia 0 1.9 0 1.9
Cardiac
Bradycardia or sinus bradycardia 3.6 0 0 0
Gastrointestinal
Diarrhea 39.3 43.4 3.6 3.8
Nausea 16.1 26.4 0 0
Stomatitis 8.9 11.3 0 0
Vomiting 12.5 18.9 1.8 1.9
General
Asthenia or fatigue 30.4 26.4 5.4 5.7
Respiratory
Cough 23.2 11.3 0 0
Skin
Alopecia 14.3 1.9 — —
Dermatitis acneiform 26.8 24.5 3.6 5.7
Dry skin 19.6 15.1 0 0
Rash 35.7 39.6 3.6 5.7
MedDRA, Medical Dictionary for Regulatory Activities.
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EGFR mutation, L858R.15–17
Limitations include the exploratory nature of the post
hoc subgroup analysis and the limited number of patients
with an EGFR mutation in MARQUEE. In addition, imbal-
ances between treatment groups with respect to KRAS
mutations and MET expression may have biased the re-
sults in favor of the erlotinib plus tivantinib group. Two
patients (4%) in the erlotinib plus placebo group had
tumors that also harbored a KRAS mutation compared
with none in the erlotinib plus tivantinib group, and the
presence of both EGFR and KRAS mutations is associated
with a worse prognosis in lung cancer.18 Likewise, MET
expression and/or gene amplification is associated with
shorter survival in lung cancer,7,8 and bothwere observed
in a slightly higher proportion of patients in the erlotinib
plus placebo group. Furthermore, baseline characteristics
were imbalanced with regard to EGFR mutation subtype,
with a higher percentage of patients in the erlotinib plus
tivantinib group harboring exon 19 deletions. Patients
with this EGFR subtype may receive greater benefit from
the combination regimen, thus potentially confounding
the conclusion of an overall benefit inEGFR-drivenNSCLC.
In conclusion, erlotinib plus tivantinib appears to
enhance efficacy in patients with previously treated,
EGFR-mutant, nonsquamous NSCLC compared with erlo-
tinib alone, but confirmatory studies are needed. Takentogether, the data from this exploratory analysis and from
the previous subset analysis of MARQUEE support the
hypothesis that the combination of an EGFR inhibitor and
a MET inhibitor may be most effective in patients with
tumors expressing high levels of MET and/or with
activating EGFR mutations.
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